echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 115 pharmaceutical companies reported third-quarter earnings forecasts for a 110-fold increase in the net profit of Sanxiang Bio.

    115 pharmaceutical companies reported third-quarter earnings forecasts for a 110-fold increase in the net profit of Sanxiang Bio.

    • Last Update: 2020-10-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network October 19 - As of October 15, a total of 115 pharmaceutical and biological listed companies in A-shares announced the first three quarters of this year's results.
    of these, 56 were pre-increased or slightly increased, 22 were pre-reduced or slightly decreased, 14 had a first loss, 13 had continued losses, 4 had turned a loss, 1 had a continuing profit and 5 were uncertain.
    from the increase or decrease in net profit, more than half of enterprises forecast an increase in net profit. figure
    1 has disclosed the first three quarters of this year's results of pharmaceutical enterprises forecast net profit source: Tonghuashun, China Kang Industrial Capital Research Center from the third-tier industry, announced the results of 115 pharmaceutical bio-listed enterprises including medical equipment 35, chemical preparations 25, Chinese medicine 17, biological products 15, chemical raw materials 10, medical services 9, pharmaceutical business 4.
    below to see the performance of the segment.
    01, the performance of medical device enterprises is still outstanding, the highest net profit pre-increase of 110 times does not count as the undecloded change in net profit of enterprises, forecast the first three quarters of this year's net profit growth rate ceiling TOP 10 enterprises, in addition to the national agricultural technology is a chemical agent enterprises, the remaining 9 are medical device enterprises.
    is worth noting that Guo Nong Technology is a turnaround, due to the acquisition of Beijing Zhiying Network An Technology Co., Ltd. 100% stake at the end of last year.
    agricultural technology originally the main business is biomedicine, but in recent years has transformed into mobile Internet game operations related services, is now not a pharmaceutical company.
    also turned a loss is Jiuan Medical, since the listing, the company's performance is not very stable, showing a change in profit and loss, small profits and losses.
    affected by the outbreak, Jiuan Medical continued to turn a profit in the first three quarters of the year with products represented by the thermometer.
    addition to Guonong Technology and Jiu'an Medical, the remaining eight medical device enterprises are pre-increased, and the maximum net profit is expected to increase 110 times, for Sanxiang Biological.
    Figure 2 predicts that the first three quarters of this year's net profit growth rate ceiling TOP 10 enterprise source: Tonghuashun, Zhongkang Industrial Capital Research Center Sanxiang Biological is a typical out-of-body diagnostic enterprises rushed out of the outbreak.
    , which has been doticing for 12 years, is known for the outbreak and landed on the board at the end of August this year under the aura of "the first wave of anti-epidemic".
    According to the company's corrected first three-quarter earnings forecast, revenue is expected to reach 3.6 billion yuan (about 3 billion yuan before correction) in the first three quarters of this year, up 1381.47 percent year-on-year; the main reason for the
    earnings forecast correction is the recurrence of overseas outbreaks in the third quarter and even the second wave of outbreaks in some countries, and the third quarter began to enter the influenza-high autumn and winter season, many countries around the world to increase the prevention and control forces to prepare for autumn and winter, to prevent the new crown and influenza common epidemic, to avoid cross-infection input, which led to the company's new coronary nucleic acid testing reagents, nucleic acid testing equipment, related supplies and other products demand for a substantial increase.
    has a profound background, product advantages, while the rise of overseas business, it can be said that the outbreak has become an opportunity for its birth, changed the growth trajectory of sanxiang creatures.
    , the company's performance may also face a correction after the outbreak ends.
    , the larger increase in net profit is expected to be Zhende Medical, Daan Gene, Taikang Medical, the forecast net profit growth ceiling of more than 10 times.
    , more than 70% of the 35 medical device companies expect net profit to grow.
    this year, under the influence of the epidemic, the performance of medical device sub-sectors, such as new crown testing, protective supplies, ventilators, CT and other products related to the outbreak, the performance of production enterprises is superior.
    from the current medical device enterprises in the third quarter of the performance forecast, the impact of the epidemic has been a certain continuation, related enterprises continue to benefit from the outbreak.
    same time, because the number of medical institutions across the country outpatients, surgery volume, etc. are still gradually recovering, so the needs of the epidemic-related medical enterprises to fully recover to the level of the same period last year will take some time.
    Chart 3 The medical device enterprises announced in the first three quarters are sourced: Tonghuashun, Zhongkang Industrial Capital Research Center 02, medical services and chemicals sector enterprises first loss in the first three quarters of the forecast net profit decreased by the lowest lower limit of the lower ten Among enterprises, medical services and chemicals enterprises, all accounted for 4 seats, respectively, Yihua Health, International Medicine, ST Hua Plastics, American Health and Asia-Pacific Pharmaceuticals, Yanyuan Pharmaceuticals, Jinshi Subpharma, Cylon Pharmaceuticals.
    , Yihua Health expects net profit to fall 6641.23% to 8949.90% year-on-year, the biggest drop among the 115 pharmaceutical companies.
    note that these 10 enterprises are basically the first loss.
    Figure 4 forecast the first three quarters of net profit year-on-year change of the lower limit TOP 10 enterprise source: Tonghuashun, Zhongkang Industrial Capital Research Center in fact, with the improvement of the epidemic, the performance of medical services sector enterprises in the gradual recovery, business conditions improved.
    Statistics show that the first quarter of this year, A-share 24 pharmaceutical services enterprises revenue fell 13.43 percent year-on-year, net profit fell 120.56 percent, while in the middle of the year, the overall revenue of these enterprises fell 2.37 percent year-on-year, net profit increased 8.53 percent year-on-year, the performance is clearly recovering.
    While the nine medical service companies that have disclosed their results so far are mostly loss-making, medical service companies still have more unannoled third-quarter earnings forecasts, especially those with high business climate CXO, which is expected to raise the overall performance level of the sector.
    of the 25 chemicals companies, net profit increased year-on-year and 13 fell year-on-year.
    in the net profit growth of enterprises, most of the performance changes are partly affected by non-recurring profit and loss.
    of the companies that reported a decline in net profit, most reported a 50-400 per cent decline, with the exception of Asia Pacific Pharmaceuticals, which expects net profit to fall by thousands of percentage points.
    Asia-Pacific Pharmaceuticals' first loss was due to the company's public issuance of convertible corporate bonds to charge interest, resulting in an increase in financial costs, the transfer of the company's production base to Shaoxing Binhai New Town, the corresponding depreciation costs, water and electricity and labor wages, the impact of the epidemic sales decline. figure
    Figure 5 the first three quarters of the announcement of the chemical preparation enterprises source: Tonghuashun, Zhongkang Industrial Capital Research Center 03, summarized in the pharmaceutical industry in 7 sub-sectors, from the forecast of the first three quarters of negative net profit growth and the number of loss-making enterprises accounted for the data, medical devices and chemical raw materials in the field of better performance, while medical services and pharmaceutical business sector performance is poor.
    , however, only some companies have disclosed earnings forecasts, such as medical services and pharmaceutical businesses to disclose the number of companies with relatively few results forecasts, the data comparability is weak. Figure
    6 Pharmaceutical enterprises in various sub-sectors of the first three quarters of this year net profit forecast statistical sources: Tonghuashun, Zhongkang Industrial Capital Research Center, however, it is undeniable that the internal division of the pharmaceutical sector is obvious, especially some medical device enterprises performance growth is better, the epidemic to its promotion role continues.
    and the main products are not related to the outbreak of some enterprises, as the outbreak is further controlled, performance is rebounding trend, of course, this will require more enterprises to disclose the first three quarters of data to further verify.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.